{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T18:07:07Z","timestamp":1789495627354,"version":"build-2803163510"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-09586-8","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T18:13:22Z","timestamp":1751393602000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Hepatic arterial infusion chemotherapy with Folfox 4 regimen versus cisplatin and gemcitabine for locally advanced intrahepatic cholangiocarcinoma"],"prefix":"10.1038","volume":"15","author":[{"given":"Lin","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huanhuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yufang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xutian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,1]]},"reference":[{"issue":"6","key":"9586_CR1","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/j.clinre.2020.03.024","volume":"44","author":"MM Gad","year":"2020","unstructured":"Gad, M. M. et al. Epidemiology of cholangiocarcinoma; united States incidence and mortality trends. Clin. Res. Hepatol. Gastroenterol. 44 (6), 885\u2013893 (2020).","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"issue":"2","key":"9586_CR2","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.canlet.2015.09.008","volume":"379","author":"H Zhang","year":"2016","unstructured":"Zhang, H., Yang, T., Wu, M. & Shen, F. Intrahepatic cholangiocarcinoma: epidemiology, risk factors, diagnosis and surgical management. Cancer Lett. 379 (2), 198\u2013205 (2016).","journal-title":"Cancer Lett."},{"key":"9586_CR3","doi-asserted-by":"crossref","unstructured":"Burger, I. et al. Geschwind. Transcatheter arterial chemoembolization in unresectable cholangiocarcinoma: initial experience in a single institution. J Vasc Interv Radiol. 16(3):353\u2009\u201361. (2005).","DOI":"10.1097\/01.RVI.0000143768.60751.78"},{"issue":"6","key":"9586_CR4","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1016\/j.jhep.2014.01.021","volume":"60","author":"J Bridgewater","year":"2014","unstructured":"Bridgewater, J. et al. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J. Hepatol. 60 (6), 1268\u20131289 (2014).","journal-title":"J. Hepatol."},{"issue":"4","key":"9586_CR5","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1159\/000449339","volume":"5","author":"T Yoh","year":"2016","unstructured":"Yoh, T. et al. Is surgical resection justified for advanced intrahepatic cholangiocarcinoma? Liver Cancer. 5 (4), 280\u2013289 (2016).","journal-title":"Liver Cancer"},{"key":"9586_CR6","unstructured":"John, N. et al. Capecitabine compared with observation in resected biliary tract cancer (bilcap): a randomised, controlled, multicentre, phase 3 study. Lancet Oncol. 20(5):663\u2013673. (2019)."},{"key":"9586_CR7","doi-asserted-by":"publisher","first-page":"101936","DOI":"10.1016\/j.ctrv.2019.101936","volume":"84","author":"A Lamarca","year":"2020","unstructured":"Lamarca, A. et al. Current standards and future perspectives in adjuvant treatment for biliary tract cancers. Cancer Treat. Rev. 84, 101936 (2020).","journal-title":"Cancer Treat. Rev."},{"issue":"2","key":"9586_CR8","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1245\/s10434-007-9627-x","volume":"15","author":"JC Tan","year":"2008","unstructured":"Tan, J. C., Coburn, N. G., Baxter, N. N., Kiss, A. & Law, C. H. Surgical management of intrahepatic cholangiocarcinoma\u2013a population-based study. Ann. Surg. Oncol. 15 (2), 600\u2013608 (2008).","journal-title":"Ann. Surg. Oncol."},{"issue":"14","key":"9586_CR9","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","volume":"362","author":"J Valle","year":"2010","unstructured":"Valle, J. et al. ABC-02 trial investigators. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl. J. Med. 362 (14), 1273\u20131281 (2010).","journal-title":"N Engl. J. Med."},{"issue":"5","key":"9586_CR10","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1053\/jhep.2002.33156","volume":"35","author":"CM Lo","year":"2002","unstructured":"Lo, C. M., Ngan, H., Tso, W. K., Liu, C. L. & Lam, C. M. Ronnie Tung-Ping poon, Sheung-Tat fan, John wong. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35 (5), 1164\u20131171 (2002).","journal-title":"Hepatology"},{"issue":"1","key":"9586_CR11","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s11605-007-0312-y","volume":"12","author":"J Niraj","year":"2008","unstructured":"Niraj, J. et al. Treatment of unresectable cholangiocarcinoma with gemcitabine-based transcatheter arterial chemoembolization (tace): a single-institution experience. J. Gastrointest. Surg. 12 (1), 129\u2013137 (2008).","journal-title":"J. Gastrointest. Surg."},{"key":"9586_CR12","unstructured":"Jan, B. et al. Fischer. Treatment of unresectable cholangiocarcinoma: conventional transarterial chemoembolization compared with drug eluting bead-transarterial chemoembolization and systemic chemotherapy. Eur J Gastroenterol Hepatol. 24(4):437\u2009\u2013\u200943. (2012)."},{"issue":"2","key":"9586_CR13","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1245\/s10434-009-0777-x","volume":"17","author":"A Saxena","year":"2010","unstructured":"Saxena, A., Bester, L., Chua, T. C., Chu, F. C. & Morris, D. L. Yttrium-90 radiotherapy for unresectable intrahepatic cholangiocarcinoma: a preliminary assessment of this novel treatment option. Ann. Surg. Oncol. 17 (2), 484\u2013491 (2010).","journal-title":"Ann. Surg. Oncol."},{"issue":"2","key":"9586_CR14","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1007\/s00270-012-0463-4","volume":"36","author":"SM Shoaib Rafi","year":"2013","unstructured":"Shoaib Rafi, S. M. et al. Yttrium-90 radioembolization for unresectable standard-chemorefractory intrahepatic cholangiocarcinoma: survival, efficacy, and safety study. Cardiovasc. Intervent Radiol. 36 (2), 440\u2013448 (2013).","journal-title":"Cardiovasc. Intervent Radiol."},{"issue":"5","key":"9586_CR15","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1159\/000508724","volume":"9","author":"S Kazuomi Ueshima","year":"2020","unstructured":"Kazuomi Ueshima, S. et al. Kengo nagashima, Yoshihiko ooka, Masahiro takita, Masayuki kurosaki, Kazuaki chayama, Shuichi kaneko, Namiki izumi, Naoya kato, Masatoshi kudo, Masao omata. Hepatic arterial infusion chemotherapy versus Sorafenib in patients with advanced hepatocellular carcinoma. Liver Cancer. 9 (5), 583\u2013595 (2020).","journal-title":"Liver Cancer"},{"issue":"2","key":"9586_CR16","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1200\/JCO.21.00608","volume":"40","author":"QJ Li","year":"2022","unstructured":"Li, Q. J. et al. Ming shi. Hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin versus transarterial chemoembolization for large hepatocellular carcinoma: a randomized phase Iii trial. J. Clin. Oncol. 40 (2), 150\u2013160 (2022).","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"9586_CR17","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1200\/JCO.21.01963","volume":"40","author":"X Ning Lyu","year":"2022","unstructured":"Ning Lyu, X. et al. Ming zhao. Arterial chemotherapy of oxaliplatin plus fluorouracil versus Sorafenib in advanced hepatocellular carcinoma: a biomolecular exploratory, randomized, phase Iii trial (fohaic-1). J. Clin. Oncol. 40 (5), 468\u2013480 (2022).","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"9586_CR18","doi-asserted-by":"publisher","first-page":"709e1","DOI":"10.1016\/j.crad.2021.03.022","volume":"76","author":"AHK Abdelmaksoud","year":"2021","unstructured":"Abdelmaksoud, A. H. K. et al. Hepatic arterial infusion chemotherapy in the treatment of advanced hepatocellular carcinoma with portal vein thrombosis: a case-control study. Clin. Radiol. 76 (9), 709e1\u2013709e6 (2021).","journal-title":"Clin. Radiol."},{"issue":"1","key":"9586_CR19","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ad.2019.05.009","volume":"112","author":"A Freites-Martinez","year":"2021","unstructured":"Freites-Martinez, A., Santana, N., Arias-Santiago, S. & Viera, A. Using the common terminology criteria for adverse events (ctcae - version 5.0) to evaluate the severity of adverse events of anticancer therapies. Actas Dermosifiliogr (Engl Ed). 112 (1), 90\u201392 (2021).","journal-title":"Actas Dermosifiliogr (Engl Ed)"},{"issue":"1","key":"9586_CR20","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21708","volume":"72","author":"RL Siegel","year":"2022","unstructured":"Siegel, R. L., Miller, K. D., Fuchs, H. E. & Jemal, A. Cancer statistics, 2022. CA Cancer J. Clin. 72 (1), 7\u201333 (2022).","journal-title":"CA Cancer J. Clin."},{"issue":"1","key":"9586_CR21","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1097\/SLA.0b013e318176c4d3","volume":"248","author":"M Itaru Endo","year":"2008","unstructured":"Itaru Endo, M. et al. Lawrence schwartz, Nancy kemeny, Eileen o\u2019reilly, Ghassan K Abou-Alfa, Hiroshi shimada, Leslie H blumgart, William R jarnagin. Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection. Ann. Surg. 248 (1), 84\u201396 (2008).","journal-title":"Ann. Surg."},{"issue":"9","key":"9586_CR22","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.3390\/cancers14092137","volume":"14","author":"E Woods","year":"2022","unstructured":"Woods, E., Le, D., Jakka, B. K. & Manne, A. Changing landscape of systemic therapy in biliary tract cancer. Cancers (Basel). 14 (9), 2137 (2022).","journal-title":"Cancers (Basel)"},{"issue":"7","key":"9586_CR23","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1002\/cncr.23787","volume":"113","author":"JH Kim","year":"2008","unstructured":"Kim, J. H. et al. Transcatheter arterial chemoembolization or chemoinfusion for unresectable intrahepatic cholangiocarcinoma: clinical efficacy and factors influencing outcomes. Cancer 113 (7), 1614\u20131622 (2008).","journal-title":"Cancer"},{"issue":"7","key":"9586_CR24","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1002\/cncr.25625","volume":"117","author":"V Matthew","year":"2011","unstructured":"Matthew, V. et al. Chemoembolization of intrahepatic cholangiocarcinoma with cisplatinum, doxorubicin, mitomycin c, ethiodol, and Polyvinyl alcohol: a 2-center study. Cancer 117 (7), 1498\u20131505 (2011).","journal-title":"Cancer"},{"issue":"3","key":"9586_CR25","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1002\/ijc.26407","volume":"131","author":"J Thomas","year":"2012","unstructured":"Thomas, J. et al. J\u00f6rg trojan, Tatjana Gruber-Rouh. Transarterial chemoembolization in the treatment of patients with unresectable cholangiocarcinoma: results and prognostic factors governing treatment success. Int. J. Cancer. 131 (3), 733\u2013740 (2012).","journal-title":"Int. J. Cancer"},{"issue":"4","key":"9586_CR26","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.crad.2010.11.002","volume":"66","author":"SY Park","year":"2011","unstructured":"Park, S. Y. et al. Transarterial chemoembolization versus supportive therapy in the palliative treatment of unresectable intrahepatic cholangiocarcinoma. Clin. Radiol. 66 (4), 322\u2013328 (2011).","journal-title":"Clin. Radiol."},{"issue":"3","key":"9586_CR27","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1038\/bjc.2016.191","volume":"115","author":"C Mosconi","year":"2016","unstructured":"Mosconi, C. et al. Yttrium-90 radioembolization for unresectable\/recurrent intrahepatic cholangiocarcinoma: a survival, efficacy and safety study. Br. J. Cancer. 115 (3), 297\u2013302 (2016).","journal-title":"Br. J. Cancer"},{"key":"9586_CR28","doi-asserted-by":"crossref","unstructured":"Mosconi, C. et al. Update of the Bologna experience in radioembolization of intrahepatic cholangiocarcinoma. Technol. Cancer Res. Treat. 22, 15330338231155690 (2023).","DOI":"10.1177\/15330338231155690"},{"key":"9586_CR29","doi-asserted-by":"crossref","unstructured":"Nancy, E. K. et al. 1,, Peter Allen, William R Jarnaginintrahepatic cholangiocarcinoma with yttrium-90 radioembolization: a systematic review and pooled analysis. Eur J Surg Oncol. 41(1):120-7. (2015).","DOI":"10.1016\/j.ejso.2014.09.007"},{"issue":"1","key":"9586_CR30","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1001\/jamaoncol.2019.3702","volume":"6","author":"J Edeline","year":"2020","unstructured":"Edeline, J. et al. Radioembolization plus chemotherapy for first-line treatment of locally advanced intrahepatic cholangiocarcinoma: a phase 2 clinical trial. JAMA Oncol. 6 (1), 51\u201359 (2020).","journal-title":"JAMA Oncol."},{"issue":"2","key":"9586_CR31","first-page":"176","volume":"10","author":"WD Ensminger","year":"1983","unstructured":"Ensminger, W. D. & Gyves, J. W. Clinical Pharmacology of hepatic arterial chemotherapy. Semin Oncol. 10 (2), 176\u2013182 (1983).","journal-title":"Semin Oncol."},{"issue":"9","key":"9586_CR32","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1093\/annonc\/mdp029","volume":"20","author":"WR Jarnagin","year":"2009","unstructured":"Jarnagin, W. R. et al. Regional chemotherapy for unresectable primary liver cancer: results of a phase Ii clinical trial and assessment of dce-mri as a biomarker of survival. Ann. Oncol. 20 (9), 1589\u20131595 (2009).","journal-title":"Ann. Oncol."},{"issue":"3\u20134","key":"9586_CR33","first-page":"153","volume":"80","author":"E Nancy","year":"2011","unstructured":"Nancy, E. et al. Peter allen, William R jarnagin. Treating primary liver cancer with hepatic arterial infusion of Floxuridine and dexamethasone: does the addition of systemic bevacizumab improve results? Oncology 80 (3\u20134), 153\u2013159 (2011).","journal-title":"Oncology"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-09586-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-09586-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-09586-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T18:13:36Z","timestamp":1751393616000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-09586-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["9586"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-09586-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,1]]},"assertion":[{"value":"19 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All patients provided written informed consent before enrollment. This is non-randomized controlled trial which was approved by the institutional review board of the First Hospital of Xian Jiaotong University (Approval number: XJTU1AF2016LSL-034) and was performed in accordance with the Declaration of Helsinki of 1975 as revised in 1983. This study was also registered at  (ChiCTR-INR-17010977).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"21588"}}